Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

Kristen Meldi, Tingting Qin, Francesca Buchi, Nathalie Droin, Jason Sotzen, Jean Baptiste Micol, Dorothée Selimoglu-Buet, Erico Masala, Bernardino Allione, Daniela Gioia, Antonella Poloni, Monia Lunghi, Eric Solary, Omar Abdel-Wahab, Valeria Santini, Maria Figueroa

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to predict which patients will benefit. Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis. While somatic mutations did not differentiate responders from nonresponders, we identified 167 differentially methylated regions (DMRs) of DNA at baseline that distinguished responders from nonresponders using next-generation sequencing. These DMRs were primarily localized to nonpromoter regions and overlapped with distal regulatory enhancers. Using the methylation profiles, we developed an epigenetic classifier that accurately predicted DAC response at the time of diagnosis. Transcriptional analysis revealed differences in gene expression at diagnosis between responders and nonresponders. In responders, the upregulated genes included those that are associated with the cell cycle, potentially contributing to effective DAC incorporation. Treatment with CXCL4 and CXCL7, which were overexpressed in nonresponders, blocked DAC effects in isolated normal CD34+ and primary CMML cells, suggesting that their upregulation contributes to primary DAC resistance.

Original languageEnglish (US)
Pages (from-to)1857-1872
Number of pages16
JournalJournal of Clinical Investigation
Volume125
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

decitabine
Leukemia, Myelomonocytic, Chronic
DNA Methylation
Epigenomics
Mutation
Gene Expression
DNA
Myelodysplastic Syndromes
Methyltransferases
Methylation
Genes
Cell Cycle
Up-Regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. / Meldi, Kristen; Qin, Tingting; Buchi, Francesca; Droin, Nathalie; Sotzen, Jason; Micol, Jean Baptiste; Selimoglu-Buet, Dorothée; Masala, Erico; Allione, Bernardino; Gioia, Daniela; Poloni, Antonella; Lunghi, Monia; Solary, Eric; Abdel-Wahab, Omar; Santini, Valeria; Figueroa, Maria.

In: Journal of Clinical Investigation, Vol. 125, No. 5, 01.01.2015, p. 1857-1872.

Research output: Contribution to journalArticle

Meldi, K, Qin, T, Buchi, F, Droin, N, Sotzen, J, Micol, JB, Selimoglu-Buet, D, Masala, E, Allione, B, Gioia, D, Poloni, A, Lunghi, M, Solary, E, Abdel-Wahab, O, Santini, V & Figueroa, M 2015, 'Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia', Journal of Clinical Investigation, vol. 125, no. 5, pp. 1857-1872. https://doi.org/10.1172/JCI78752
Meldi, Kristen ; Qin, Tingting ; Buchi, Francesca ; Droin, Nathalie ; Sotzen, Jason ; Micol, Jean Baptiste ; Selimoglu-Buet, Dorothée ; Masala, Erico ; Allione, Bernardino ; Gioia, Daniela ; Poloni, Antonella ; Lunghi, Monia ; Solary, Eric ; Abdel-Wahab, Omar ; Santini, Valeria ; Figueroa, Maria. / Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. In: Journal of Clinical Investigation. 2015 ; Vol. 125, No. 5. pp. 1857-1872.
@article{4803a7ec9e4f433db7371174079c70e6,
title = "Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia",
abstract = "Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to predict which patients will benefit. Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis. While somatic mutations did not differentiate responders from nonresponders, we identified 167 differentially methylated regions (DMRs) of DNA at baseline that distinguished responders from nonresponders using next-generation sequencing. These DMRs were primarily localized to nonpromoter regions and overlapped with distal regulatory enhancers. Using the methylation profiles, we developed an epigenetic classifier that accurately predicted DAC response at the time of diagnosis. Transcriptional analysis revealed differences in gene expression at diagnosis between responders and nonresponders. In responders, the upregulated genes included those that are associated with the cell cycle, potentially contributing to effective DAC incorporation. Treatment with CXCL4 and CXCL7, which were overexpressed in nonresponders, blocked DAC effects in isolated normal CD34+ and primary CMML cells, suggesting that their upregulation contributes to primary DAC resistance.",
author = "Kristen Meldi and Tingting Qin and Francesca Buchi and Nathalie Droin and Jason Sotzen and Micol, {Jean Baptiste} and Doroth{\'e}e Selimoglu-Buet and Erico Masala and Bernardino Allione and Daniela Gioia and Antonella Poloni and Monia Lunghi and Eric Solary and Omar Abdel-Wahab and Valeria Santini and Maria Figueroa",
year = "2015",
month = "1",
day = "1",
doi = "10.1172/JCI78752",
language = "English (US)",
volume = "125",
pages = "1857--1872",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

AU - Meldi, Kristen

AU - Qin, Tingting

AU - Buchi, Francesca

AU - Droin, Nathalie

AU - Sotzen, Jason

AU - Micol, Jean Baptiste

AU - Selimoglu-Buet, Dorothée

AU - Masala, Erico

AU - Allione, Bernardino

AU - Gioia, Daniela

AU - Poloni, Antonella

AU - Lunghi, Monia

AU - Solary, Eric

AU - Abdel-Wahab, Omar

AU - Santini, Valeria

AU - Figueroa, Maria

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to predict which patients will benefit. Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis. While somatic mutations did not differentiate responders from nonresponders, we identified 167 differentially methylated regions (DMRs) of DNA at baseline that distinguished responders from nonresponders using next-generation sequencing. These DMRs were primarily localized to nonpromoter regions and overlapped with distal regulatory enhancers. Using the methylation profiles, we developed an epigenetic classifier that accurately predicted DAC response at the time of diagnosis. Transcriptional analysis revealed differences in gene expression at diagnosis between responders and nonresponders. In responders, the upregulated genes included those that are associated with the cell cycle, potentially contributing to effective DAC incorporation. Treatment with CXCL4 and CXCL7, which were overexpressed in nonresponders, blocked DAC effects in isolated normal CD34+ and primary CMML cells, suggesting that their upregulation contributes to primary DAC resistance.

AB - Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to predict which patients will benefit. Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis. While somatic mutations did not differentiate responders from nonresponders, we identified 167 differentially methylated regions (DMRs) of DNA at baseline that distinguished responders from nonresponders using next-generation sequencing. These DMRs were primarily localized to nonpromoter regions and overlapped with distal regulatory enhancers. Using the methylation profiles, we developed an epigenetic classifier that accurately predicted DAC response at the time of diagnosis. Transcriptional analysis revealed differences in gene expression at diagnosis between responders and nonresponders. In responders, the upregulated genes included those that are associated with the cell cycle, potentially contributing to effective DAC incorporation. Treatment with CXCL4 and CXCL7, which were overexpressed in nonresponders, blocked DAC effects in isolated normal CD34+ and primary CMML cells, suggesting that their upregulation contributes to primary DAC resistance.

UR - http://www.scopus.com/inward/record.url?scp=84928982643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928982643&partnerID=8YFLogxK

U2 - 10.1172/JCI78752

DO - 10.1172/JCI78752

M3 - Article

C2 - 25822018

AN - SCOPUS:84928982643

VL - 125

SP - 1857

EP - 1872

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -